EXICURE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 0.00 shares.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 0.00 shares.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 0.00 shares.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 124.00 shares, a 99.96% decline from fiscal 2021.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 342.25K shares, a 31.67% decline from fiscal 2020.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 500.90K shares, a 480.67% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-06-17 | 0.00 shares derived: sum of 4 quarters · filed 2024-06-17 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | 0.00 shares 10-K · filed 2024-06-06 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-05-16 | 0.00 shares derived: sum of 4 quarters · filed 2024-06-06 |
| 2023-06-30 | 0.00 shares derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-06-06 | 0.00 shares derived: sum of 4 quarters · filed 2024-06-06 |
| 2023-03-31 | 0.00 shares 10-Q/A · filed 2024-06-06 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | 124.00 shares 10-K · filed 2024-06-06 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | 342.25K shares 10-K · filed 2022-03-25 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-19 | 765.01K shares derived: sum of 4 quarters · filed 2021-11-19 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 787.25K shares derived: sum of 4 quarters · filed 2021-11-19 |
| 2021-03-31 | 342.25K shares 10-Q · filed 2021-05-12 | 843.15K shares derived: sum of 4 quarters · filed 2021-11-19 |
| 2020-12-31 | 422.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 500.90K shares 10-K · filed 2021-03-11 |
| 2020-09-30 | 22.24K shares 10-Q · filed 2021-11-19 | 152.61K shares derived: sum of 4 quarters · filed 2021-11-19 |
| 2020-06-30 | 55.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | 130.37K shares derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-12 | 86.26K shares derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | 74.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | 86.26K shares 10-K · filed 2020-03-10 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 11.79K shares derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | 11.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 25.75K shares derived: sum of 4 quarters · filed 2019-09-23 |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-08 | 13.96K shares derived: sum of 4 quarters · filed 2019-09-23 |
| 2018-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | 22.49K shares 10-K/A · filed 2019-09-23 |
| 2018-09-30 | 13.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 22.49K shares derived: sum of 4 quarters · filed 2018-11-06 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | |
| 2018-03-31 | 8.53K shares 10-Q · filed 2018-05-15 | |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | 58.44K shares 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |